Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications [...].
Keywords: TNF-alpha; adalimumab; cancer; certolizumab; etanercept; golimumab; infliximab; meta-analysis.